Vivos Therapeutics Inc increased III. Quarter net loss per share of $-0.26 compare to net loss per share of $-0.26 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.33 realized in previous quarter.
III. Quarter
Earnings Per Share
Revenues
$ -0.26
$
4 Mill
Unch.
Unch.-6.6 %
Vivos Therapeutics Inc 's Revenue
fell by
-6.6 % in III. Quarter (Sep 30 2022) year on year,
to $4 million and
advanced by
1.48 % sequentially.
Vivos Therapeutics Inc is Expected to report next financial results on March 30, 2023.
Vivos Therapeutics Inc 's
in III. Quarter recorded net loss of $-5.434 million, an improvement compare to net loss of $-5.453 million in III. Quarter a year ago.
Sequentially
net loss narrowed from net loss of $-6.992 million realized in previous quarter.
In III. Quarter company's net cash and cash equivalents decreased by $-6 million, capital expenditures grew by -77.30%, to $0 millions compare to same quarter a year ago and rose by -80.16% from II. Quarter (Jun 30 2022).
